PIK3CA mutations in human solid tumors Role in sensitivity to various therapeutic approaches

被引：175

作者：

Ligresti, Giovanni ^{[1
]}

Militello, Loredana ^{[1
]}

Steelman, Linda S. ^{[2
,3
]}

Cavallaro, Andrea ^{[1
]}

Basile, Francesco

Nicoletti, Ferdinando ^{[1
]}

Stivala, Franca ^{[1
]}

McCubrey, James A. ^{[2
,3
]}

Libra, Massimo ^{[1
]}

机构：

[1] Univ Catania, Dept Biomed Sci, I-95124 Catania, Italy

[2] Univ Catania, Dept Surg, I-95124 Catania, Italy

[3] E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC USA

来源：

CELL CYCLE | 2009年 / 8卷 / 09期

关键词：

PIK3CA; gene mutations; PI3K pathway; AKT; cancer; TRASTUZUMAB RESISTANCE; HIGH-FREQUENCY; PTEN FUNCTION; HUMAN CANCER; 3-KINASE; GENE; MECHANISM; OVARIAN; GROWTH; CELLS;

D O I：

10.4161/cc.8.9.8255

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Phosphatidylinositol 3-kinases (PI3Ks) are a group of lipid kinases that regulate signaling pathways involved in cell proliferation, adhesion, survival and motility. The PI3K pathway is considered to play an important role in tumorigenesis. Activating mutations of the p110a subunit of PI3K (PIK3CA) have been identified in a broad spectrum of tumors. Analyses of PIK3CA mutations reveals that they increase the PI3K signal, stimulate downstream Akt signaling, promote growth factor-independent growth and increase cell invasion and metastasis. In this review, we analyze the contribution of the PIK3CA mutations in cancer, and their possible implications for diagnosis and therapy.

引用

页码：1352 / 1358

页数：7

共 40 条

[1] A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt [J].

Aoki, M ;

Blazek, E ;

Vogt, PK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) :136-141

[2] Cancer-specific mutations in PIK3CA are oncogenic in vivo [J].

Bader, AG ;

Kang, SY ;

Vogt, PK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) :1475-1479

[3] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[4] PKB binding proteins: Getting in on the akt [J].

Brazil, DP ;

Park, J ;

Hemmings, BA .

CELL, 2002, 111 (03) :293-303

[5] Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas [J].

Broderick, DK ;

Di, CH ;

Parrett, TJ ;

Samuels, YR ;

Cummins, JM ;

McLendon, RE ;

Fults, DW ;

Velculescu, VE ;

Bigner, DD ;

Yan, H .

CANCER RESEARCH, 2004, 64 (15) :5048-5050

[6] Mutation of the PIK3CA gene in ovarian and breast cancer [J].

Campbell, IG ;

Russell, SE ;

Choong, DYH ;

Montgomery, KG ;

Ciavarella, ML ;

Hooi, CSF ;

Cristiano, BE ;

Pearson, RB ;

Phillips, WA .

CANCER RESEARCH, 2004, 64 (21) :7678-7681

[7] The phosphoinositide 3-kinase pathway [J].

Cantley, LC .

SCIENCE, 2002, 296 (5573) :1655-1657

[8] Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction [J].

Corvera, S ;

Czech, MP .

TRENDS IN CELL BIOLOGY, 1998, 8 (11) :442-446

[9] PI 3-KINASE - STRUCTURAL AND FUNCTIONAL-ANALYSIS OF INTERSUBUNIT INTERACTIONS [J].

DHAND, R ;

HARA, K ;

HILES, I ;

BAX, B ;

GOUT, I ;

PANAYOTOU, G ;

FRY, MJ ;

YONEZAWA, K ;

KASUGA, M ;

WATERFIELD, MD .

EMBO JOURNAL, 1994, 13 (03) :511-521

[10] Ribosomal S6 kinase signaling and the control of translation [J].

Dufner, A ;

Thomas, G .

EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :100-109

← 1 2 3 4 →